Identification

Name
Pentamidine
Accession Number
DB00738  (APRD00303, EXPT02625)
Type
Small Molecule
Groups
Approved, Investigational
Description

Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. [PubChem]

Structure
Thumb
Synonyms
  • 1,5-Bis(4-amidinophenoxy)pentane
  • 4,4'-(1,5-Pentanediylbis(oxy))bis-benzenecarboximidamide
  • 4,4'-(Pentamethylenedioxy)dibenzamidine
  • 4,4'-Diamidinodiphenoxypentane
  • P,P'-(pentamethylenedioxy)dibenzamidine
  • Pentamidin
  • Pentamidina
  • Pentamidindiisetionat
  • Pentamidine
  • Pentamidinum
External IDs
MB 800 / RP 2512
Product Ingredients
IngredientUNIICASInChI Key
Pentamidine gluconateB0WU872RIR123245-08-9JAVCHNFPSHBZAF-UUPCJSQJSA-N
Pentamidine IsethionateV2P3K60DA2140-64-7YBVNFKZSMZGRAD-UHFFFAOYSA-N
Pentamidine mesylate863QBB4D0A6823-79-6WRXSODAXJSKMAW-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
NebuPentInhalant300 mg/6mLRespiratory (inhalation)Fresenius Kabi2011-02-15Not applicableUs
Pentacarinat 300 Inj Pws 300mg/vialPowder, for solution300 mgIntramuscular; Intravenous; Respiratory (inhalation)Aventis Pharma Ltd.1989-12-312005-08-01Canada
Pentam 300Injection, powder, lyophilized, for solution300 mg/3mLIntramuscular; IntravenousAPP Pharmaceuticals, Inc.2001-01-16Not applicableUs
Pentamidine Isethionate Inj 300mg/vial BPPowder, for solution300 mgIntramuscular; IntravenousDavid Bull Laboratories (Pty) Ltd.1990-12-311998-08-13Canada
Pentamidine Isetionate for Injection BPPowder, for solution300 mgIntramuscular; IntravenousPfizer1998-09-10Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Pentamidine IsethionateInjection, powder, lyophilized, for solution300 mg/300mgIntramuscular; IntravenousSeton Pharmaceuticals2013-09-01Not applicableUs
International/Other Brands
Pentacarinat (Sanofi-Aventis) / Pentacrinat (Abbot) / Pentam (Abbot) / Pentamidine isethionate (Abbot) / Pneumopent
Categories
UNII
673LC5J4LQ
CAS number
100-33-4
Weight
Average: 340.4195
Monoisotopic: 340.189926032
Chemical Formula
C19H24N4O2
InChI Key
XDRYMKDFEDOLFX-UHFFFAOYSA-N
InChI
InChI=1S/C19H24N4O2/c20-18(21)14-4-8-16(9-5-14)24-12-2-1-3-13-25-17-10-6-15(7-11-17)19(22)23/h4-11H,1-3,12-13H2,(H3,20,21)(H3,22,23)
IUPAC Name
4-{[5-(4-carbamimidoylphenoxy)pentyl]oxy}benzene-1-carboximidamide
SMILES
NC(=N)C1=CC=C(OCCCCCOC2=CC=C(C=C2)C(N)=N)C=C1

Pharmacology

Indication

For the treatment of pneumonia due to Pneumocystis carinii.

Associated Conditions
Pharmacodynamics

Pentamidine is an antiprotozoal agent. It is an aromatic diamidine, and is known to have activity against Pneumocystis carinii. The exact nature of its antiprotozoal action is unknown. in vitro studies with mammalian tissues and the protozoan Crithidia oncopelti indicate that the drug interferes with nuclear metabolism producing inhibition of the synthesis of DNA, RNA, phospholipids and proteins. Little is known about the drug's pharmacokinetics. The medication is also useful in Leishmaniasis and in prophylaxis against sleeping sickness caused by Trypanosoma brucei gambiense. Hydration before treatment lessens the incidence and severity of side effects, which include liver or kidney dysfunction, hypertension, hypotension, hypoglycemia, hypocalemia, leukopenia, thrombcytopenia, anemia, and allergic reaction. It is generally well-tolerated.

Mechanism of action

The mode of action of pentamidine is not fully understood. It is thought that the drug interferes with nuclear metabolism producing inhibition of the synthesis of DNA, RNA, phospholipids, and proteins.

TargetActionsOrganism
UDNA
intercalation
Human
UtRNA (cytosine(38)-C(5))-methyltransferase
other
Human
Absorption

Absorbed poorly through the gastrointestinal tract and is usually administered parenterally.

Volume of distribution
Not Available
Protein binding

69%

Metabolism

Hepatic.

Route of elimination
Not Available
Half life

9.1-13.2 hours

Clearance
Not Available
Toxicity

Symptoms of overdose include pain, nausea, anorexia, hypotension, fever, rash, bad taste in mouth, confusion/hallucinations, dizziness, and diarrhea.

Affected organisms
  • Pneumocystis carinii
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINEThe therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Pentamidine.Experimental
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Pentamidine.Investigational
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Pentamidine.Experimental
AbirateroneThe serum concentration of Pentamidine can be increased when it is combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Pentamidine.Approved, Investigational
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Pentamidine.Approved, Investigational, Withdrawn
Acetyl sulfisoxazoleThe metabolism of Pentamidine can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Pentamidine.Approved, Vet Approved
AgmatineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Agmatine.Experimental, Investigational
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Pentamidine.Experimental, Investigational
AlaproclateAlaproclate may increase the hypoglycemic activities of Pentamidine.Experimental
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Pentamidine.Investigational
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Pentamidine.Approved
AloxiprinAloxiprin may increase the hypoglycemic activities of Pentamidine.Experimental
AmantadineAmantadine may increase the QTc-prolonging activities of Pentamidine.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Pentamidine.Approved
AmiodaronePentamidine may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Pentamidine.Approved
AmlodipineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Amlodipine.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Pentamidine.Approved
AmphetamineAmphetamine may increase the hypoglycemic activities of Pentamidine.Approved, Illicit, Investigational
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Pentamidine.Approved, Investigational
AmrinoneThe therapeutic efficacy of Pentamidine can be increased when used in combination with Amrinone.Approved
AnagrelidePentamidine may increase the QTc-prolonging activities of Anagrelide.Approved
ApalutamideThe serum concentration of Pentamidine can be decreased when it is combined with Apalutamide.Approved, Investigational
ApomorphineApomorphine may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
AprepitantThe serum concentration of Pentamidine can be increased when it is combined with Aprepitant.Approved, Investigational
AranidipineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Aranidipine.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
ArmodafinilThe metabolism of Pentamidine can be decreased when combined with Armodafinil.Approved, Investigational
Arsenic trioxidePentamidine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherPentamidine may increase the QTc-prolonging activities of Artemether.Approved
AsenapinePentamidine may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirThe metabolism of Pentamidine can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Pentamidine can be decreased when combined with Atomoxetine.Approved
AzelnidipineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Azelnidipine.Approved, Investigational
AzimilideThe therapeutic efficacy of Pentamidine can be increased when used in combination with Azimilide.Investigational
AzithromycinAzithromycin may increase the QTc-prolonging activities of Pentamidine.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Pentamidine.Investigational
BalsalazideBalsalazide may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
BarnidipineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Barnidipine.Approved
BedaquilinePentamidine may increase the QTc-prolonging activities of Bedaquiline.Approved
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Pentamidine.Investigational
BencyclaneThe therapeutic efficacy of Pentamidine can be increased when used in combination with Bencyclane.Experimental
BenidipineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Benidipine.Approved, Investigational
BenmoxinBenmoxin may increase the hypoglycemic activities of Pentamidine.Withdrawn
BepridilThe therapeutic efficacy of Pentamidine can be increased when used in combination with Bepridil.Approved, Withdrawn
BetaxololThe metabolism of Pentamidine can be decreased when combined with Betaxolol.Approved, Investigational
BioallethrinThe therapeutic efficacy of Pentamidine can be increased when used in combination with Bioallethrin.Approved, Experimental
BoceprevirThe metabolism of Pentamidine can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Pentamidine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Pentamidine can be decreased when it is combined with Bosentan.Approved, Investigational
BrofaromineBrofaromine may increase the hypoglycemic activities of Pentamidine.Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Pentamidine.Investigational, Withdrawn
BupropionThe metabolism of Pentamidine can be decreased when combined with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
BuspironeThe metabolism of Buspirone can be decreased when combined with Pentamidine.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Pentamidine.Approved, Investigational
CaffeineThe metabolism of Pentamidine can be decreased when combined with Caffeine.Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pentamidine.Approved
CarbamazepineThe metabolism of Pentamidine can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may increase the hypoglycemic activities of Pentamidine.Experimental, Investigational
CarboxyamidotriazoleThe therapeutic efficacy of Pentamidine can be increased when used in combination with Carboxyamidotriazole.Investigational
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Pentamidine.Experimental
CaroverineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Caroverine.Experimental
CaroxazoneCaroxazone may increase the hypoglycemic activities of Pentamidine.Withdrawn
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Pentamidine.Experimental
CelecoxibThe metabolism of Pentamidine can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Pentamidine can be increased when it is combined with Ceritinib.Approved
ChloramphenicolThe metabolism of Pentamidine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational, Vet Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational, Vet Approved
ChlorpropamideChlorpropamide may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
CholecalciferolThe metabolism of Pentamidine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Pentamidine.Experimental
CilnidipineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Cilnidipine.Approved, Investigational
CimetidineThe metabolism of Pentamidine can be decreased when combined with Cimetidine.Approved, Investigational
CinacalcetThe metabolism of Pentamidine can be decreased when combined with Cinacalcet.Approved
CinnarizineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Cinnarizine.Approved, Investigational
CinoxacinCinoxacin may increase the hypoglycemic activities of Pentamidine.Approved, Investigational, Withdrawn
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Pentamidine.Approved, Investigational, Withdrawn
CitalopramPentamidine may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinThe metabolism of Pentamidine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Pentamidine can be decreased when combined with Clemastine.Approved, Investigational
ClevidipineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Clevidipine.Approved, Investigational
ClobazamThe metabolism of Pentamidine can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineThe metabolism of Pentamidine can be decreased when combined with Clomipramine.Approved, Investigational, Vet Approved
ClotrimazoleThe metabolism of Pentamidine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Pentamidine.Approved
CobicistatThe serum concentration of Pentamidine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Pentamidine can be decreased when combined with Cocaine.Approved, Illicit
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Pentamidine.Approved, Investigational
CrisaboroleThe metabolism of Pentamidine can be decreased when combined with Crisaborole.Approved, Investigational
CrizotinibPentamidine may increase the QTc-prolonging activities of Crizotinib.Approved
CurcuminThe metabolism of Pentamidine can be decreased when combined with Curcumin.Approved, Investigational
CyclandelateThe therapeutic efficacy of Pentamidine can be increased when used in combination with Cyclandelate.Approved
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Pentamidine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Pentamidine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Pentamidine can be decreased when it is combined with Dabrafenib.Approved, Investigational
DapoxetineDapoxetine may increase the hypoglycemic activities of Pentamidine.Investigational
DarifenacinThe metabolism of Pentamidine can be decreased when combined with Darifenacin.Approved, Investigational
DarodipineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Darodipine.Experimental
DarunavirThe serum concentration of Pentamidine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Pentamidine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Pentamidine can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Pentamidine.Approved
DelamanidPentamidine may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
DelavirdineThe metabolism of Pentamidine can be decreased when combined with Delavirdine.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Pentamidine.Investigational
DersalazineDersalazine may increase the hypoglycemic activities of Pentamidine.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Pentamidine.Approved
DesipramineThe metabolism of Pentamidine can be decreased when combined with Desipramine.Approved, Investigational
DesvenlafaxineDesvenlafaxine may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
DeutetrabenazinePentamidine may increase the QTc-prolonging activities of Deutetrabenazine.Approved, Investigational
DidanosineDidanosine can cause a decrease in the absorption of Pentamidine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DiflunisalDiflunisal may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
DihydroergotamineThe metabolism of Pentamidine can be decreased when combined with Dihydroergotamine.Approved, Investigational
DiltiazemThe metabolism of Pentamidine can be decreased when combined with Diltiazem.Approved, Investigational
DiphenhydramineThe metabolism of Pentamidine can be decreased when combined with Diphenhydramine.Approved, Investigational
DisopyramidePentamidine may increase the QTc-prolonging activities of Disopyramide.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Pentamidine.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Pentamidine.Approved, Investigational
DolasetronPentamidine may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
DomperidonePentamidine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DosulepinThe metabolism of Pentamidine can be decreased when combined with Dosulepin.Approved
DotarizineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Dotarizine.Investigational
DoxepinDoxepin may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
DoxycyclineThe metabolism of Pentamidine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaronePentamidine may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Pentamidine.Approved, Vet Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Pentamidine.Approved, Investigational
DuloxetineThe metabolism of Pentamidine can be decreased when combined with Duloxetine.Approved
EfavirenzThe metabolism of Pentamidine can be decreased when combined with Efavirenz.Approved, Investigational
EfonidipineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Efonidipine.Approved, Investigational
EliglustatPentamidine may increase the QTc-prolonging activities of Eliglustat.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Pentamidine.Approved
EnglitazoneThe therapeutic efficacy of Englitazone can be decreased when used in combination with Pentamidine.Experimental
EnoxacinEnoxacin may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
EnzalutamideThe serum concentration of Pentamidine can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe therapeutic efficacy of Pentamidine can be increased when used in combination with Eperisone.Approved, Investigational
EribulinEribulin may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational, Vet Approved
EscitalopramPentamidine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Pentamidine can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Pentamidine can be decreased when combined with Esomeprazole.Approved, Investigational
EthosuximideThe therapeutic efficacy of Pentamidine can be increased when used in combination with Ethosuximide.Approved
EtoperidoneEtoperidone may increase the hypoglycemic activities of Pentamidine.Withdrawn
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Pentamidine.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Pentamidine.Approved, Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
FamotidineFamotidine may increase the QTc-prolonging activities of Pentamidine.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Pentamidine.Approved
FelodipineThe metabolism of Pentamidine can be decreased when combined with Felodipine.Approved, Investigational
FendilineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Fendiline.Withdrawn
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pentamidine.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
Fish oilThe therapeutic efficacy of Pentamidine can be increased when used in combination with Fish oil.Approved, Nutraceutical
FlecainidePentamidine may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FleroxacinFleroxacin may increase the hypoglycemic activities of Pentamidine.Approved
FluconazoleThe metabolism of Pentamidine can be decreased when combined with Fluconazole.Approved, Investigational
FlumequineFlumequine may increase the hypoglycemic activities of Pentamidine.Withdrawn
FlunarizineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Flunarizine.Approved
FluoxetinePentamidine may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Pentamidine.Approved, Illicit
FlupentixolPentamidine may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational, Withdrawn
FluspirileneThe therapeutic efficacy of Pentamidine can be increased when used in combination with Fluspirilene.Approved, Investigational
FluvoxamineThe metabolism of Pentamidine can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
FosamprenavirThe metabolism of Pentamidine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Pentamidine can be increased when it is combined with Fosaprepitant.Approved
FoscarnetThe risk or severity of adverse effects can be increased when Pentamidine is combined with Foscarnet.Approved
FosphenytoinThe serum concentration of Pentamidine can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FurazolidoneFurazolidone may increase the hypoglycemic activities of Pentamidine.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Pentamidine can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe therapeutic efficacy of Pentamidine can be increased when used in combination with Gabapentin.Approved, Investigational
Gadobenic acidPentamidine may increase the QTc-prolonging activities of Gadobenic acid.Approved, Investigational
GalantamineGalantamine may increase the QTc-prolonging activities of Pentamidine.Approved
GallopamilThe therapeutic efficacy of Pentamidine can be increased when used in combination with Gallopamil.Investigational
GarenoxacinGarenoxacin may increase the hypoglycemic activities of Pentamidine.Investigational
GatifloxacinGatifloxacin may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
GemfibrozilThe metabolism of Pentamidine can be decreased when combined with Gemfibrozil.Approved
GemifloxacinPentamidine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Pentamidine.Investigational, Withdrawn
GliclazidePentamidine may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideGlimepiride may increase the hypoglycemic activities of Pentamidine.Approved
GlipizidePentamidine may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Pentamidine.Approved, Investigational
GLPG-0492GLPG-0492 may increase the hypoglycemic activities of Pentamidine.Investigational
GlyburidePentamidine may increase the hypoglycemic activities of Glyburide.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Pentamidine.Approved
GranisetronPentamidine may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GrepafloxacinGrepafloxacin may increase the hypoglycemic activities of Pentamidine.Approved, Investigational, Withdrawn
GuacetisalGuacetisal may increase the hypoglycemic activities of Pentamidine.Experimental
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Pentamidine.Investigational
HaloperidolHaloperidol may increase the QTc-prolonging activities of Pentamidine.Approved
HarmalineHarmaline may increase the hypoglycemic activities of Pentamidine.Experimental
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the hypoglycemic activities of Pentamidine.Experimental
HistrelinHistrelin may increase the QTc-prolonging activities of Pentamidine.Approved
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Pentamidine.Experimental
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Pentamidine.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
IbutilidePentamidine may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe metabolism of Pentamidine can be decreased when combined with Idelalisib.Approved
IloperidonePentamidine may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe metabolism of Pentamidine can be decreased when combined with Imatinib.Approved
ImipramineThe metabolism of Pentamidine can be decreased when combined with Imipramine.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Pentamidine.Approved
IndalpineIndalpine may increase the hypoglycemic activities of Pentamidine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Pentamidine.Approved
IndinavirThe metabolism of Pentamidine can be decreased when combined with Indinavir.Approved
Insulin AspartPentamidine may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirPentamidine may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineInsulin Glargine may increase the hypoglycemic activities of Pentamidine.Approved
Insulin GlulisinePentamidine may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanInsulin Human may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
Insulin LisproInsulin Lispro may increase the hypoglycemic activities of Pentamidine.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Pentamidine.Approved
IproclozideIproclozide may increase the hypoglycemic activities of Pentamidine.Withdrawn
IproniazidIproniazid may increase the hypoglycemic activities of Pentamidine.Withdrawn
IrbesartanThe metabolism of Pentamidine can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoleThe serum concentration of Pentamidine can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Pentamidine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Pentamidine.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Pentamidine.Approved, Vet Approved
IsoniazidThe metabolism of Pentamidine can be decreased when combined with Isoniazid.Approved, Investigational
IsradipineIsradipine may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
ItraconazoleThe metabolism of Pentamidine can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Pentamidine.Approved
IvacaftorThe serum concentration of Pentamidine can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Pentamidine can be decreased when combined with Ketoconazole.Approved, Investigational
LacidipineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Lacidipine.Approved, Investigational
LamotrigineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Lamotrigine.Approved, Investigational
LanreotidePentamidine may increase the hypoglycemic activities of Lanreotide.Approved
LapatinibThe metabolism of Pentamidine can be decreased when combined with Lapatinib.Approved, Investigational
LenvatinibPentamidine may increase the QTc-prolonging activities of Lenvatinib.Approved, Investigational
LercanidipineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Lercanidipine.Approved, Investigational
LeuprolideLeuprolide may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
LevetiracetamThe therapeutic efficacy of Pentamidine can be increased when used in combination with Levetiracetam.Approved, Investigational
LevofloxacinPentamidine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
LidocaineThe metabolism of Pentamidine can be decreased when combined with Lidocaine.Approved, Vet Approved
LidoflazineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Lidoflazine.Experimental
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Pentamidine.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Pentamidine.Approved
Lithium cationLithium may increase the QTc-prolonging activities of Pentamidine.Experimental
LobeglitazoneThe metabolism of Pentamidine can be decreased when combined with Lobeglitazone.Approved, Investigational
LomefloxacinLomefloxacin may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
LoperamideThe therapeutic efficacy of Pentamidine can be increased when used in combination with Loperamide.Approved
LopinavirPentamidine may increase the QTc-prolonging activities of Lopinavir.Approved
LorcaserinThe metabolism of Pentamidine can be decreased when combined with Lorcaserin.Approved
LorpiprazoleThe serum concentration of Pentamidine can be increased when it is combined with Lorpiprazole.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Pentamidine.Approved
LovastatinThe metabolism of Pentamidine can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Pentamidine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Pentamidine can be increased when it is combined with Lumacaftor.Approved
LumefantrinePentamidine may increase the QTc-prolonging activities of Lumefantrine.Approved
MacimorelinPentamidine may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
Magnesium sulfateThe therapeutic efficacy of Pentamidine can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineThe metabolism of Pentamidine can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineMaprotiline may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
MebanazineMebanazine may increase the hypoglycemic activities of Pentamidine.Withdrawn
MecaserminPentamidine may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MefloquineMefloquine may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
MentholThe therapeutic efficacy of Pentamidine can be increased when used in combination with Menthol.Approved
MequitazinePentamidine may increase the arrhythmogenic activities of Mequitazine.Approved
MesalazineMesalazine may increase the hypoglycemic activities of Pentamidine.Approved
MesteroloneMesterolone may increase the hypoglycemic activities of Pentamidine.Experimental
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Pentamidine.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Pentamidine.Approved
MethotrimeprazineThe metabolism of Pentamidine can be decreased when combined with Methotrimeprazine.Approved, Investigational
MethsuximideThe therapeutic efficacy of Pentamidine can be increased when used in combination with Methsuximide.Approved
Methyl salicylateMethyl salicylate may increase the hypoglycemic activities of Pentamidine.Approved, Vet Approved
Methylene blueMethylene blue may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Pentamidine.Approved
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Pentamidine.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Pentamidine.Approved
MexiletineThe metabolism of Pentamidine can be decreased when combined with Mexiletine.Approved, Investigational
MibefradilThe therapeutic efficacy of Pentamidine can be increased when used in combination with Mibefradil.Investigational, Withdrawn
MidostaurinThe metabolism of Pentamidine can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneMifepristone may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
MifepristoneThe serum concentration of Pentamidine can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Pentamidine.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Pentamidine.Approved
MilnacipranMilnacipran may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
MinaprineMinaprine may increase the hypoglycemic activities of Pentamidine.Approved
MirabegronThe metabolism of Pentamidine can be decreased when combined with Mirabegron.Approved
MirtazapineMirtazapine may increase the QTc-prolonging activities of Pentamidine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Pentamidine.Approved, Investigational
MitotaneThe serum concentration of Pentamidine can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Pentamidine can be decreased when combined with Moclobemide.Approved, Investigational
ModafinilThe metabolism of Pentamidine can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Pentamidine.Approved
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
NabiloneThe metabolism of Pentamidine can be decreased when combined with Nabilone.Approved, Investigational
NaftopidilThe therapeutic efficacy of Pentamidine can be increased when used in combination with Naftopidil.Investigational
Nalidixic AcidNalidixic Acid may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
NandroloneNandrolone may increase the hypoglycemic activities of Pentamidine.Experimental, Investigational
Nandrolone decanoateNandrolone decanoate may increase the hypoglycemic activities of Pentamidine.Approved, Illicit
NateglinideNateglinide may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
NefazodoneThe metabolism of Pentamidine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Pentamidine can be decreased when combined with Nelfinavir.Approved
NemonoxacinNemonoxacin may increase the hypoglycemic activities of Pentamidine.Investigational
NetupitantThe serum concentration of Pentamidine can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Pentamidine can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypoglycemic activities of Pentamidine.Withdrawn
NicardipineNicardipine may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
NifedipineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Nifedipine.Approved
NiguldipineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Niguldipine.Experimental
NilotinibPentamidine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NiludipineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Niludipine.Experimental
NilvadipineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Nilvadipine.Approved, Investigational
NimesulideThe therapeutic efficacy of Pentamidine can be increased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Nimodipine.Approved, Investigational
NisoldipineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Nisoldipine.Approved
NitrendipineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Nitrendipine.Approved, Investigational
NitroaspirinNitroaspirin may increase the hypoglycemic activities of Pentamidine.Investigational
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Pentamidine.Approved
NortriptylineNortriptyline may increase the QTc-prolonging activities of Pentamidine.Approved
NylidrinThe therapeutic efficacy of Pentamidine can be increased when used in combination with Nylidrin.Approved
OctamoxinOctamoxin may increase the hypoglycemic activities of Pentamidine.Withdrawn
OctreotideOctreotide may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
OfloxacinPentamidine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
OlaparibThe metabolism of Pentamidine can be decreased when combined with Olaparib.Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Pentamidine.Approved
OlsalazineOlsalazine may increase the hypoglycemic activities of Pentamidine.Approved
OmeprazoleThe metabolism of Pentamidine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronPentamidine may increase the QTc-prolonging activities of Ondansetron.Approved
OsimertinibThe serum concentration of Pentamidine can be increased when it is combined with Osimertinib.Approved
OtiloniumThe therapeutic efficacy of Pentamidine can be increased when used in combination with Otilonium.Experimental, Investigational
OxandroloneOxandrolone may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
Oxolinic acidOxolinic acid may increase the hypoglycemic activities of Pentamidine.Experimental
OxymetholoneOxymetholone may increase the hypoglycemic activities of Pentamidine.Approved, Illicit
OxytocinOxytocin may increase the QTc-prolonging activities of Pentamidine.Approved, Vet Approved
PalbociclibThe serum concentration of Pentamidine can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidonePentamidine may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatThe serum concentration of Pentamidine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Pentamidine can be decreased when combined with Pantoprazole.Approved
PargylinePargyline may increase the hypoglycemic activities of Pentamidine.Approved
ParoxetineThe metabolism of Pentamidine can be decreased when combined with Paroxetine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Pentamidine.Approved
PazopanibPentamidine may increase the QTc-prolonging activities of Pazopanib.Approved
PazufloxacinPazufloxacin may increase the hypoglycemic activities of Pentamidine.Investigational
PefloxacinPefloxacin may increase the hypoglycemic activities of Pentamidine.Approved
Peginterferon alfa-2bThe serum concentration of Pentamidine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PegvisomantPegvisomant may increase the hypoglycemic activities of Pentamidine.Approved
PentobarbitalThe metabolism of Pentamidine can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PerflutrenPerflutren may increase the QTc-prolonging activities of Pentamidine.Approved
PhenelzinePhenelzine may increase the hypoglycemic activities of Pentamidine.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Pentamidine.Approved, Investigational, Withdrawn
PheniprazinePheniprazine may increase the hypoglycemic activities of Pentamidine.Withdrawn
PhenobarbitalThe metabolism of Pentamidine can be increased when combined with Phenobarbital.Approved, Investigational
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Pentamidine.Withdrawn
Phenyl aminosalicylatePhenyl aminosalicylate may increase the hypoglycemic activities of Pentamidine.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Pentamidine.Approved, Vet Approved
PimozidePentamidine may increase the QTc-prolonging activities of Pimozide.Approved
PinaveriumThe therapeutic efficacy of Pentamidine can be increased when used in combination with Pinaverium.Approved
PioglitazoneThe metabolism of Pentamidine can be decreased when combined with Pioglitazone.Approved, Investigational
Pipemidic acidPipemidic acid may increase the hypoglycemic activities of Pentamidine.Experimental
PirlindolePirlindole may increase the hypoglycemic activities of Pentamidine.Approved
Piromidic acidPiromidic acid may increase the hypoglycemic activities of Pentamidine.Experimental
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Pentamidine.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Pentamidine.Withdrawn
PosaconazoleThe metabolism of Pentamidine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Pentamidine.Approved, Investigational
PrenylamineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Prenylamine.Withdrawn
PrimaquinePentamidine may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Pentamidine can be increased when combined with Primidone.Approved, Vet Approved
ProcainamidePentamidine may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineProcaine may increase the hypoglycemic activities of Pentamidine.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
ProgesteroneThe absorption of Progesterone can be decreased when combined with Pentamidine.Approved, Vet Approved
PromazinePromazine may increase the QTc-prolonging activities of Pentamidine.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
PropafenonePentamidine may increase the QTc-prolonging activities of Propafenone.Approved
PropofolPropofol may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational, Vet Approved
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Pentamidine.Approved
PrulifloxacinPrulifloxacin may increase the hypoglycemic activities of Pentamidine.Investigational
QuetiapinePentamidine may increase the QTc-prolonging activities of Quetiapine.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Pentamidine.Approved, Investigational
QuininePentamidine may increase the QTc-prolonging activities of Quinine.Approved
RabeprazoleThe metabolism of Pentamidine can be decreased when combined with Rabeprazole.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Pentamidine.Approved, Investigational
RanolazineThe metabolism of Pentamidine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypoglycemic activities of Pentamidine.Approved
RepaglinidePentamidine may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RibociclibThe risk or severity of QTc prolongation can be increased when Ribociclib is combined with Pentamidine.Approved, Investigational
RifabutinThe metabolism of Pentamidine can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Pentamidine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Pentamidine can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Pentamidine.Approved, Investigational
RilpivirineRilpivirine may increase the QTc-prolonging activities of Pentamidine.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
RitonavirThe metabolism of Pentamidine can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Pentamidine can be decreased when combined with Rolapitant.Approved, Investigational
RopiniroleThe metabolism of Pentamidine can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneThe metabolism of Pentamidine can be decreased when combined with Rosiglitazone.Approved, Investigational
RosoxacinRosoxacin may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
RucaparibThe metabolism of Pentamidine can be decreased when combined with Rucaparib.Approved, Investigational
RufloxacinRufloxacin may increase the hypoglycemic activities of Pentamidine.Experimental
SafrazineSafrazine may increase the hypoglycemic activities of Pentamidine.Withdrawn
SalbutamolSalbutamol may increase the QTc-prolonging activities of Pentamidine.Approved, Vet Approved
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Pentamidine.Approved, Investigational, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Pentamidine.Approved
SaquinavirThe metabolism of Pentamidine can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Pentamidine can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Pentamidine.Approved
SecobarbitalThe metabolism of Pentamidine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineSelegiline may increase the hypoglycemic activities of Pentamidine.Approved, Investigational, Vet Approved
SeletracetamThe therapeutic efficacy of Pentamidine can be increased when used in combination with Seletracetam.Investigational
SertralineThe metabolism of Pentamidine can be decreased when combined with Sertraline.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Pentamidine.Approved, Vet Approved
SildenafilThe metabolism of Pentamidine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Pentamidine can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Pentamidine can be increased when it is combined with Simeprevir.Approved
SitafloxacinSitafloxacin may increase the hypoglycemic activities of Pentamidine.Experimental, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Pentamidine.Approved, Investigational
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Pentamidine.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Pentamidine.Investigational
SotalolPentamidine may increase the QTc-prolonging activities of Sotalol.Approved
SparfloxacinSparfloxacin may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
St. John's WortThe serum concentration of Pentamidine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanoloneStanolone may increase the hypoglycemic activities of Pentamidine.Illicit, Investigational
StanozololStanozolol may increase the hypoglycemic activities of Pentamidine.Approved, Vet Approved
StiripentolThe serum concentration of Pentamidine can be increased when it is combined with Stiripentol.Approved
SucralfateSucralfate can cause a decrease in the absorption of Pentamidine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SulfadiazineSulfadiazine may increase the hypoglycemic activities of Pentamidine.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Pentamidine can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Pentamidine.Approved, Vet Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Pentamidine.Approved, Investigational
SunitinibThe metabolism of Sunitinib can be decreased when combined with Pentamidine.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Pentamidine.Approved, Investigational
TamoxifenThe metabolism of Pentamidine can be decreased when combined with Tamoxifen.Approved
TelaprevirThe metabolism of Pentamidine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelavancinPentamidine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Pentamidine can be decreased when combined with Telithromycin.Approved
TemafloxacinTemafloxacin may increase the hypoglycemic activities of Pentamidine.Withdrawn
Tenofovir disoproxilThe metabolism of Pentamidine can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerbinafineThe metabolism of Pentamidine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Pentamidine.Approved
TeriflunomideThe serum concentration of Pentamidine can be decreased when it is combined with Teriflunomide.Approved
TerodilineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Terodiline.Experimental
TestosteroneTestosterone may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
Testosterone cypionateTestosterone cypionate may increase the hypoglycemic activities of Pentamidine.Approved
Testosterone enanthateTestosterone enanthate may increase the hypoglycemic activities of Pentamidine.Approved
Testosterone propionateTestosterone propionate may increase the hypoglycemic activities of Pentamidine.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateTestosterone undecanoate may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
TetrabenazinePentamidine may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
TetrahydropalmatineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Tetrahydropalmatine.Investigational
TheophyllineThe metabolism of Pentamidine can be decreased when combined with Theophylline.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Pentamidine.Approved, Withdrawn
ThiothixeneThiothixene may increase the QTc-prolonging activities of Pentamidine.Approved
TiclopidineThe metabolism of Pentamidine can be decreased when combined with Ticlopidine.Approved
TipranavirThe metabolism of Pentamidine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
TocilizumabThe serum concentration of Pentamidine can be decreased when it is combined with Tocilizumab.Approved
TolazamidePentamidine may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolbutamidePentamidine may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
Tolfenamic AcidThe therapeutic efficacy of Pentamidine can be increased when used in combination with Tolfenamic Acid.Approved, Investigational
ToloxatoneToloxatone may increase the hypoglycemic activities of Pentamidine.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
TopiramateThe metabolism of Pentamidine can be decreased when combined with Topiramate.Approved
TopiroxostatThe metabolism of Pentamidine can be decreased when combined with Topiroxostat.Approved, Investigational
ToremifenePentamidine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TranilastThe therapeutic efficacy of Pentamidine can be increased when used in combination with Tranilast.Approved, Investigational
TranylcypromineThe metabolism of Pentamidine can be decreased when combined with Tranylcypromine.Approved, Investigational
TrazodoneTrazodone may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
TrimebutineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Trimebutine.Approved
TrimethadioneThe therapeutic efficacy of Pentamidine can be increased when used in combination with Trimethadione.Approved
TrimethoprimThe metabolism of Pentamidine can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Pentamidine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Pentamidine.Approved, Vet Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Pentamidine.Investigational, Withdrawn
Trolamine salicylateTrolamine salicylate may increase the hypoglycemic activities of Pentamidine.Approved
TrovafloxacinTrovafloxacin may increase the hypoglycemic activities of Pentamidine.Approved, Investigational, Withdrawn
VandetanibPentamidine may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Pentamidine.Approved
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Pentamidine.Approved
VenlafaxineThe metabolism of Pentamidine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Pentamidine can be decreased when combined with Verapamil.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Pentamidine.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Pentamidine.Approved, Investigational
VinpocetineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Vinpocetine.Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Pentamidine.Approved, Investigational
VoriconazoleThe metabolism of Pentamidine can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
WIN 55212-2The therapeutic efficacy of Pentamidine can be increased when used in combination with WIN 55212-2.Experimental
ZiconotideThe therapeutic efficacy of Pentamidine can be increased when used in combination with Ziconotide.Approved
ZimelidineZimelidine may increase the hypoglycemic activities of Pentamidine.Withdrawn
ZiprasidonePentamidine may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Pentamidine.Approved
ZonisamideThe therapeutic efficacy of Pentamidine can be increased when used in combination with Zonisamide.Approved, Investigational
ZucapsaicinThe metabolism of Pentamidine can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolPentamidine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Nguewa PA, Fuertes MA, Cepeda V, Iborra S, Carrion J, Valladares B, Alonso C, Perez JM: Pentamidine is an antiparasitic and apoptotic drug that selectively modifies ubiquitin. Chem Biodivers. 2005 Oct;2(10):1387-400. [PubMed:17191940]
External Links
Human Metabolome Database
HMDB0014876
KEGG Compound
C07420
PubChem Compound
4735
PubChem Substance
46508562
ChemSpider
4573
BindingDB
45440
ChEBI
45081
ChEMBL
CHEMBL55
Therapeutic Targets Database
DAP000764
PharmGKB
PA450850
HET
PNT
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Pentamidine
ATC Codes
P01CX01 — Pentamidine isethionate
AHFS Codes
  • 08:30.92 — Miscellaneous Antiprotozoals
PDB Entries
1d64 / 1rkw / 3cr4 / 3cr5 / 3ey0 / 3gy3 / 3hii
MSDS
Download (50.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHepatocellular,Carcinoma1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Pneumonia, Pneumocystis Carinii2
1RecruitingPreventionHypertrophic Scars1
1RecruitingTreatmentHepatic Steatosis1
1, 2CompletedTreatmentColorectal Cancers1
1, 2CompletedTreatmentKidney Diseases / Transplantation, Kidney1
1, 2CompletedTreatmentMalignant Neoplasm of Pancreas1
2CompletedNot AvailableMalignancies, Hematologic1
2CompletedTreatmentDiabetes Mellitus, Insulin-Dependent1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Pneumonia, Pneumocystis Carinii1
2CompletedTreatmentMalignant Lymphomas1
2CompletedTreatmentMelanoma (Skin)1
2CompletedTreatmentTrypanosoma brucei gambiense infection1
2, 3RecruitingTreatmentLeishmania Braziliensis Complex / Leishmaniasis, American / Leishmaniasis, Cutaneous / Leishmaniasis; American, Cutaneous1
3CompletedPreventionHuman Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) / Visceral Leishmaniosis1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Pneumonia, Pneumocystis Carinii6
3TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Pneumonia, Pneumocystis Carinii1
4WithdrawnTreatmentPneumonia, Pneumocystis Carinii1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Pneumonia, Pneumocystis Carinii10

Pharmacoeconomics

Manufacturers
  • App pharmaceuticals llc
  • Armour pharmaceutical co
  • Baxter healthcare corp anesthesia and critical care
  • Hospira inc
  • Watson laboratories inc
Packagers
  • APP Pharmaceuticals
  • APPD
  • Baxter International Inc.
  • Hospira Inc.
  • Physicians Total Care Inc.
Dosage forms
FormRouteStrength
InhalantRespiratory (inhalation)300 mg/6mL
Powder, for solutionIntramuscular; Intravenous; Respiratory (inhalation)300 mg
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous300 mg/3mL
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous300 mg/300mg
Powder, for solutionIntramuscular; Intravenous300 mg
Prices
Unit descriptionCostUnit
Nebupent 300 mg inhal powder122.84USD each
Pentam 300 vial94.8USD vial
Pentamidine 300 mg vial45.31USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)186.0 °C (decomposes)Not Available
water solubilityCompleteNot Available
logP4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0236 mg/mLALOGPS
logP1.32ALOGPS
logP2.32ChemAxon
logS-4.2ALOGPS
pKa (Strongest Basic)12.13ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area118.2 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity120.53 m3·mol-1ChemAxon
Polarizability38.85 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9416
Blood Brain Barrier+0.9133
Caco-2 permeable-0.8957
P-glycoprotein substrateNon-substrate0.5352
P-glycoprotein inhibitor INon-inhibitor0.8571
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterInhibitor0.6653
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9115
CYP450 3A4 substrateNon-substrate0.7339
CYP450 1A2 substrateNon-inhibitor0.5272
CYP450 2C9 inhibitorNon-inhibitor0.7439
CYP450 2D6 inhibitorNon-inhibitor0.7676
CYP450 2C19 inhibitorNon-inhibitor0.6581
CYP450 3A4 inhibitorNon-inhibitor0.8661
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5621
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8395
BiodegradationNot ready biodegradable0.9818
Rat acute toxicity2.2925 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7428
hERG inhibition (predictor II)Non-inhibitor0.7711
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0009000000-e30f537a55b02f867429
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0009000000-18ffa88d8e83e0c224b3
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00di-0309000000-22a206e2fffa6ce5cf2f
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00dr-0900000000-d135e9c44dbf5da10735
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00di-0900000000-d01e29cdf614c3660180
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0006-0009000000-1499530d0d768e480fd7
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0006-0009000000-3c60569ced478a95001f
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00di-0209000000-58a168dde59140860009
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00dr-0901000000-7cd36861b140e4e5a6a2
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00di-0900000000-60dfcd75868e869bcbf7
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-00di-0009000000-6677c6c06aa266d05ff1

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenol ethers
Sub Class
Not Available
Direct Parent
Phenol ethers
Alternative Parents
Phenoxy compounds / Alkyl aryl ethers / Carboximidamides / Carboxamidines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Phenoxy compound / Phenol ether / Alkyl aryl ether / Monocyclic benzene moiety / Carboximidamide / Ether / Carboxylic acid amidine / Amidine / Organic nitrogen compound / Organic oxygen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
carboxamidine, diether (CHEBI:45081)

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
Unknown
Actions
Intercalation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Shankar SM, Nania JJ: Management of Pneumocystis jiroveci pneumonia in children receiving chemotherapy. Paediatr Drugs. 2007;9(5):301-9. [PubMed:17927302]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other
General Function
Trna methyltransferase activity
Specific Function
Specifically methylates cytosine 38 in the anticodon loop of tRNA(Asp).
Gene Name
TRDMT1
Uniprot ID
O14717
Uniprot Name
tRNA (cytosine(38)-C(5))-methyltransferase
Molecular Weight
44596.17 Da
References
  1. Sun T, Zhang Y: Pentamidine binds to tRNA through non-specific hydrophobic interactions and inhibits aminoacylation and translation. Nucleic Acids Res. 2008 Mar;36(5):1654-64. doi: 10.1093/nar/gkm1180. Epub 2008 Feb 7. [PubMed:18263620]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Afrin LB, Afrin JB: Value of preemptive CYP2C19 genotyping in allogeneic stem cell transplant patients considered for pentamidine administration. Clin Transplant. 2011 May-Jun;25(3):E271-5. doi: 10.1111/j.1399-0012.2011.01399.x. Epub 2011 Feb 7. [PubMed:21299635]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Li XQ, Bjorkman A, Andersson TB, Gustafsson LL, Masimirembwa CM: Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42. Epub 2003 Aug 12. [PubMed:12920490]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Li XQ, Bjorkman A, Andersson TB, Gustafsson LL, Masimirembwa CM: Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42. Epub 2003 Aug 12. [PubMed:12920490]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Li XQ, Bjorkman A, Andersson TB, Gustafsson LL, Masimirembwa CM: Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42. Epub 2003 Aug 12. [PubMed:12920490]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Leukotriene-b4 20-monooxygenase activity
Specific Function
Catalyzes the omega- and (omega-1)-hydroxylation of various fatty acids such as laurate, myristate and palmitate. Has little activity toward prostaglandins A1 and E1. Oxidizes arachidonic acid to 2...
Gene Name
CYP4A11
Uniprot ID
Q02928
Uniprot Name
Cytochrome P450 4A11
Molecular Weight
59347.31 Da
References
  1. Li XQ, Bjorkman A, Andersson TB, Gustafsson LL, Masimirembwa CM: Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42. Epub 2003 Aug 12. [PubMed:12920490]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on July 20, 2018 19:27